Research Article

Sitagliptin: Is It Effective in Routine Clinical Practice?

Table 2

Parameter estimates using the Generalized Estimating Equations (GEE) model (imputed) ().

ParameterStd. error95% Wald confidence intervalHypothesis test
LowerUpperWald chi-squaredfSig.

(Intercept)1.990.5912.8313.14911.3261.001
Years diagnosed
 >20 years.467.2467−.016.9513.5901.058
 16–20 years.319.2447−.161.7981.6971.193
 11–15 years.366.2301−.085.8172.5281.112
 6–10 years.292.2186−.137.7201.7801.182
 1–5 years0a
Employment status
 No−.118.1402−.393.157.7071.401
 Yes0a
Race
 Indian−.116.1250−.361.129.8651.352
 Chinese−.201.1122−.421.0193.2181.073
 Malay0a
Marital status
 Widower.163.3932−.607.934.1731.678
 Divorced.274.2920−.299.846.8781.349
 Married.136.2674−.388.660.2591.611
 Single0a
Gender
 Female.047.985−.147.240.2231.637
 Male0a
Time of HbA1c level
 7–12 months after sitagliptin −.562.0941−.746−.37735.5861.000
 3–6 months after sitagliptin−.831.0801−.988−.674107.5501.000
 Before initiation of sitagliptin (Baseline)0a
Number of antidiabetes−.038 .1301−.292.217.0841.773
Age−.010.0065−.023.0032.3451.126
Changes in regimen
 During initiation of sitagliptin .101.2169−.324.526.2161.642
 After initiation of sitagliptin.020.0981−.172.213.0431.837
 No change0a
Initiation dose of sitagliptin
 100 mg.057.3022−.536.649.0351.852
 50 mg.273.2901−.295.842.8871.346
 25 mg0a
Medications prior to sitagliptin initiation
 Others.281.2851−.278.840.9691.325
 Biguanide, sulphonylurea, and insulin.384.3392−.2811.0491.2811.258
 Sulphonylurea and insulin.009.3411−.660.678.0011.979
 Biguanide and insulin.226.3094−.381.832.5331.465
 Biguanide and sulphonylurea.194.1855−.170.5581.0921.296
 Insulin alone.140.4808−.8021.083.0851.770
 Sulphonylurea alone.062.1920−.314.438.1041.747
 Biguanide alone0a
Initiation of sitagliptin
 Added to current regime−.159.1385−.431.1121.3181.251
 Switched from current regime0a
Baseline HbA1c.790.0407.711.870377.1591000
(Scale)1.114

Dependent variable: HbA1c.
aSet to zero because this parameter is redundant.